BOSTON--(BUSINESS WIRE)--GMO, a global investment manager, today announced that the GMO U.S. Quality ETF (NYSE: QLTY), has surpassed $1 billion in assets under management since launching in November 2023.
“Reaching $1 billion less than one year after the launch of QLTY illustrates that clients are seeking quality amid rising uncertainties and questions about valuation in some parts of the market. GMO is committed to offering innovative investment solutions in the structures that best address their needs,” said Scott Hayward, Chief Executive Officer of GMO.
“We are grateful that QLTY ETF has been so well-received by existing clients and those new to GMO, which we believe is indicative of the clear differentiation between our fundamental approach to investing in high-quality equities and passive strategies,” said Tom Hancock, Head of GMO Focused Equity and Portfolio Manager of QLTY.
GMO began researching quality investing in the 1980s led by Jeremy Grantham, Co-Founder and Long-Term Investment Strategist at GMO. QLTY leverages GMO’s more than 40 years of quality investing experience to invest in U.S. high-quality stocks, while offering the additional benefits of the ETF structure, including tax efficiency, daily transparency, and continuous liquidity.
GMO’s expansion into ETFs offers a structure that aligns with investors seeking tax-advantaged and operationally efficient access to long-running, institutional-grade GMO strategies, which the firm will continue to deliver with the same focus and conviction over the long term. Following the success of QLTY, GMO is exploring the opportunity to launch additional ETFs and will share additional details when available.
About GMO
Global investment manager GMO, established in 1977, brings together focused expertise within its investment teams, industry-leading research, and client solutions and service to advance clients’ goals. Privately owned and renowned for conviction in a valuation-based, long-term investment philosophy, GMO serves sophisticated institutions, financial intermediaries, and families, and managed $66 billion as of June 30, 2024. The firm is headquartered in Boston, with offices in London, Sydney, Amsterdam, San Francisco (research hub), Singapore, and Tokyo (representative office).
Risks associated with investing in the Fund may include: (1) Market Risk - Equities: The market price of an equity may decline due to factors affecting the issuer or its industry or the economy and equity markets generally. Declines in stock market prices generally are likely to reduce the net asset value of the Fund's shares. (2) Management and Operational Risk: The risk that GMO's investment techniques will fail to produce desired results. (3) Focused Investment Risk: The Fund invests its assets in the securities of a limited number of issuers, and a decline in the market price of a particular security held by the Fund may affect the Fund's performance more than if the Fund invested in the securities of a larger number of issuers. For a more complete discussion of these risks and others, please consult the Fund's prospectus.
An investor should consider the fund’s investment objectives, risks, charges, and expenses before investing. This and other important information can be found in the fund’s prospectus. A copy of the prospectus can be found here. Please read the prospectus carefully before investing.
The GMO ETFs are distributed in the United States by Foreside Fund Services LLC. GMO and Foreside Fund Services LLC are not affiliated.
